NOUS-209 is under clinical development by Nouscom and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NOUS-209’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NOUS-209 is under development for the treatment of solid tumors incuding gastric cancer, colorectal cancer and gastroesophageal junction microsatellite instable cancers. The therapeutic candidate is developed based on Exovax platform which comprises of human great apes adenovirus (GAd) and modified vaccinia virus ankara (MVA) viral vectors encoding cancer neoantigens and AGE1.CR.pIX platform. It is administered through intramuscular route.
Nouscom is a immunotherapy company. It develops a genetic neoantigen vaccine and oncolytic viruses for prevention and treatment of cancer. Nouscom is headquartered in Basel, Switzerland.
For a complete picture of NOUS-209’s drug-specific PTSR and LoA scores, buy the report here.